Young L S, Inderlied C B, Berlin O G, Gottlieb M S
Rev Infect Dis. 1986 Nov-Dec;8(6):1024-33. doi: 10.1093/clinids/8.6.1024.
Serious infections caused by the Mycobacterium avium complex (MAC) have been increasingly recognized over the last three decades. However, the epidemic of the acquired immunodeficiency syndrome (AIDS) has increased interest in these infections. Disseminated mycobacterial disease is common in patients with AIDS, and MAC is the predominant bacterial isolate. Indeed, at UCLA Medical Center, MAC organisms are now the predominant isolates in both AIDS- and non-AIDS-associated mycobacterial disease. MAC lung infections have been difficult to treat. Complex regimens employing four to six drugs are not clearly effective and are usually associated with considerable toxicity. Treatment of MAC infections in patients with AIDS has been particularly frustrating, and evidence that treatment can either eradicate disease or prolong life is limited. MAC organisms are invariably resistant to traditional antituberculosis medications. We have examined a variety of other compounds, and our findings, based on both in vitro and animal-model studies, have identified drugs which, when used in combination, are potentially of therapeutic utility.
在过去三十年中，鸟分枝杆菌复合群（MAC）引起的严重感染日益受到关注。然而，获得性免疫缺陷综合征（AIDS）的流行增加了人们对这些感染的兴趣。播散性分枝杆菌病在艾滋病患者中很常见，MAC是主要的细菌分离株。事实上，在加州大学洛杉矶分校医学中心，MAC菌现在是艾滋病相关和非艾滋病相关分枝杆菌病中的主要分离株。MAC肺部感染一直难以治疗。使用四到六种药物的复杂治疗方案效果并不明确，而且通常伴有相当大的毒性。艾滋病患者MAC感染的治疗尤其令人沮丧，治疗能够根除疾病或延长生命的证据有限。MAC菌对传统抗结核药物始终具有耐药性。我们研究了多种其他化合物，基于体外和动物模型研究的结果，我们确定了一些药物，这些药物联合使用时可能具有治疗作用。
